Alpha Cognition (OTC:ACOGF) Hits New 52-Week High – What’s Next?

Alpha Cognition Inc. (OTC:ACOGF) reached a new 52-week high on Tuesday . The company traded as high as C$8.75 and last traded at C$8.75, with a volume of 18 shares trading hands. The stock had previously closed at C$8.75.

Wall Street Analyst Weigh In

Separately, Raymond James raised Alpha Cognition from a “hold” rating to a “moderate buy” rating in a research note on Monday, July 15th.

Alpha Cognition Stock Performance

The company has a market capitalization of C$1.32 billion, a P/E ratio of -72.91 and a beta of 2.80. The stock’s fifty day moving average is C$0.40 and its 200 day moving average is C$0.48.

Alpha Cognition (OTC:ACOGF) last posted its quarterly earnings data on Monday, August 12th. The company reported C($0.01) earnings per share for the quarter, beating the consensus estimate of C($0.04) by C$0.03. On average, analysts expect that Alpha Cognition Inc. will post -0.19 EPS for the current fiscal year.

Alpha Cognition Company Profile

Alpha Cognition Inc, a clinical stage biopharmaceutical company, develops treatments for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062 for the treatment of mild-to-moderate Alzheimer’s disease and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases.